Tianjin Medical University Second Hospital

This study tests whether the drug toripalimab can stop high-risk kidney cancer from returning after surgery to remove the kidney. About 100 adults will receive the drug every three weeks for up to a year. Researchers will track how long participants stay cancer-free and monitor s…